SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
hep26686-sup-0001-suppinfo.eps376KSupporting Figure 1: Patients with LAM-R and/or ADV-R detected while on TDF or FTC/TDF. Conserved-site changes are noted in bold italics; all other changes are polymorphic. The black box in the treatment window indicates timepoints where the patient was documented to be nonadherent to study medication.
hep26686-sup-0002-suppinfo.docx19KSupporting Table 1. Resistance Surveillance Population: Number of Patients Qualifying for Genotypic Analysis at Their Last Visit on TDF or FTC/TDF

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.